Short answer
ARS Pharmaceuticals, Inc. (SPRY) filed an 8-K current report with the SEC on July 7, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Donn Casale appointed CEO effective July 7, 2026, replacing Richard Lowenthal.
ARS Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Donn Casale appointed CEO effective July 7, 2026, replacing Richard Lowenthal
- Lowenthal terminated without cause, effective immediately, creating leadership-transition risk
- Casale joins the Board as a Class III director through the 2029 annual meeting
- Existing President-to-CEO transition may support continuity in strategy and operations
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARS Pharmaceuticals, Inc. 8-K filings
Get the next SPRY 8-K as it lands
Follow SPRY for push alerts, or ask the research agent what this filing means.